US launches trade probe on Germany over pharma pricing

AI Summary

The United States commenced a trade investigation into Germany's pharmaceutical pricing mechanisms, examining whether Germany's approach results in inadequate compensation for innovative medicines and creates unfair competitive conditions for US industry. Under Section 301 trade authority, the probe could lead to new tariffs if unfair practices are confirmed. The investigation evaluates how Germany establishes and implements its pharmaceutical pricing policies.